By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mitsubishi Tanabe Pharma Corporation 

3-2-10, Dosho-machi, Chuo-ku

Osaka    541-8505  Japan
Phone: n/a Fax: n/a



Company News
FDA Accepts Mitsubishi Tanabe's NDA Filing For Edaravone To Treat ALS 8/30/2016 7:57:44 AM
Mitsubishi Tanabe Joins Certara Corporation’s Simcyp Consortium 7/20/2016 11:00:59 AM
Mitsubishi Tanabe Submits New Drug Application For Edaravone To Treat ALS In The United States 6/20/2016 7:06:51 AM
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Kyowa Hakko Kirin, Merck & Co. (MRK), Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com 6/6/2016 12:09:47 PM
Mitsubishi Tanabe Presents Edaravone Clinical Trial Data In ALS At 2016 American Academy of Neurology Annual Meeting 4/20/2016 2:41:22 PM
Mitsubishi Tanabe Signs Licensing Agreement With A. Menarini Asia-Pacific For Spedra (Avanafil) In 10 Countries In Asia-Pacific 2/26/2016 10:03:37 AM
Akebia (AKBA) And Mitsubishi Tanabe Announce Collaboration To Develop And Commercialize Vadadustat In Asia 12/14/2015 1:13:29 PM
Regeneron (REGN) Forges $325 Million Pain Pact with Mitsubishi Tanabe 10/2/2015 6:10:16 AM
MedImmune (AZN) And Tanabe Research Laboratories U.S.A., Inc./Mitsubishi Tanabe Enter Into Strategic Collaboration And Licensing Agreement For The Development Of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates To Treat Cancer 9/23/2015 1:52:15 PM
Neurocrine Biosciences, Inc. (NBIX) And Mitsubishi Tanabe Pharma Corporation Announce Agreement To Develop And Commercialize VMAT2 Inhibitor NBI-98854 For Movement Disorders In Japan And Other Select Asian Markets 4/1/2015 12:52:31 PM